Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 5/20 | 0.51 |
| ▸ | RAF1 | P04049 | 4/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.45 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.38 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2983638 | 0.89 | BRAF (0.46) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL2984640 | 0.87 | BRAF (0.43) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL2976253 | 0.84 | BRAF (0.51) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL27688654 | 0.84 | BRAF (0.43) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL2971985 | 0.83 | BRAF (0.46) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL2973478 | 0.79 | BRAF (0.52) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL2986664 | 0.79 | BRAF (0.45) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL2983500 | 0.79 | BRAF (0.46) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL2983611 | 0.78 | BRAF (0.47) | BRAFRAF1SCN9AIRAK1IRAK4 | |
| SCHEMBL2977811 | 0.77 | BRAF (0.49) | BRAFRAF1IRAK1IRAK4MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| CN-101115749-B | Aminopyrimidine compounds and methods of use | AMGEN INC | 2011-06-22 | — | — | CN | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| CN-101115749-A | Aminopyrimidine compounds and methods of use | AMGEN INC (US) | 2008-01-30 | — | — | CN | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | BRAF 841/4885RAF1 1089/4885SCN9A 4768/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | BRAF 841/4885RAF1 1089/4885SCN9A 4768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.